Department of Medicine, Washington University School of Medicine, Washington University, Saint Louis, MO 63110, USA.
PPAR Res. 2008;2008:374549. doi: 10.1155/2008/374549.
The peroxisome proliferator-activated receptors (PPARs) consist of three related transcription factors that serve to regulate a number of cellular processes that are central to cardiovascular health and disease. Numerous pharmacologic studies have assessed the effects of specific PPAR agonists in clinical trials and have provided insight into the clinical effects of these genes while genetic studies have demonstrated clinical associations between PPAR polymorphisms and abnormal cardiovascular phenotypes. With the abundance of data available from these studies as a background, PPAR pharmacogenetics has become a promising and rapidly advancing field. This review focuses on summarizing the current state of understanding of PPAR genetics and pharmacogenetics and the important implications for the individualization of therapy for patients with cardiovascular diseases.
过氧化物酶体增殖物激活受体（PPARs）由三种相关的转录因子组成，它们在心血管健康和疾病中起着调节许多细胞过程的作用。许多药理学研究已经在临床试验中评估了特定的 PPAR 激动剂的作用，并深入了解了这些基因的临床作用，而遗传研究则表明 PPAR 多态性与心血管表型异常之间存在临床关联。在这些研究提供的大量数据的背景下，PPAR 药物遗传学已成为一个有前途且快速发展的领域。本综述重点总结了目前对 PPAR 遗传学和药物遗传学的理解，并对心血管疾病患者个体化治疗的重要意义进行了总结。
